GENELUX CORPORATION Operating Lease Right-of-Use Assets
GENELUX CORPORATION (GNLX) had Operating Lease Right-of-Use Assets of $2.31 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:OperatingLeaseRightOfUseAsset · last filed 2026-08-13
- 2026-06-30: Operating Lease, Right-of-Use Asset $2.31M.
- 2026-03-31: Operating Lease, Right-of-Use Asset $2.39M.
- 2025-12-31: Operating Lease, Right-of-Use Asset $1.58M.
- 2025-09-30: Operating Lease, Right-of-Use Asset $1.52M.
| Period end | Operating Lease, Right-of-Use Asset |
|---|---|
| 2026-06-30 | $2.31M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $2.39M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $1.58M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $1.52M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $1.60M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $1.68M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $1.76M 10-K · filed 2026-03-19 |
| 2024-09-30 | $1.93M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $2.10M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $2.26M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $2.43M 10-K · filed 2025-03-28 |
| 2023-09-30 | $1.78M 10-Q · filed 2023-11-14 |
| 2023-07-31 | $909.00K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $1.71M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $1.85M 10-Q · filed 2023-05-15 |
| 2023-02-28 | $649.00K 10-Q · filed 2023-08-14 |
| 2022-12-31 | $1.33M 10-K · filed 2024-03-29 |
| 2022-06-30 | $1.33M 10-Q · filed 2023-08-14 |
| 2022-04-30 | $860.00K 10-Q · filed 2023-11-14 |
| 2021-07-31 | $656.00K 10-Q · filed 2023-05-15 |
| 2020-12-31 | $439.00K 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |